Investment Rating - The report maintains a "Buy" rating for EUDA Health Holdings Limited with a target price of $2.75, down from a previous target of $6.00 [10]. Core Insights - EUDA has made significant progress in expanding its stem cell business, transitioning from a third-party distributor to a vertically integrated stem cell therapy company capable of rapid growth in China [10]. - Despite delays in the Helixé product's progress leading to a downward revision of short-term revenue forecasts, the management's focus on building a portfolio of longevity and health products remains attractive for long-term growth [10]. - The revenue forecast for 2026 has been adjusted down to $27.23 million, reflecting a significant impact from the issuance of new shares and a reduction in expected Helixé product sales from 105,000 bottles to 50,000 bottles [9][10]. Market Data - Current stock price is $0.73 with a market capitalization of $36.73 million [1]. - The company has a 52-week trading range of $0.70 to $4.30 and an average daily trading volume of 523,000 shares [1]. - Institutional ownership is at 2%, while insider ownership stands at 37% [1]. Financial Overview - The company reported cash of $0.17 million, short-term debt of $2.06 million, and a long-term debt of $0.00 million [1]. - The EBITDA for the past 12 months is reported at $(1.85) million, indicating ongoing operational losses [1]. Business Expansion - In January 2026, EUDA agreed to a RMB 6 million convertible loan to upgrade its cGMP production facilities in Shenzhen, aimed at creating an advanced center for stem cell therapy [2]. - The company has launched a nationwide stem cell extraction, cryopreservation, and clinical delivery platform in collaboration with Inno and Wuhan Kane Hospital [3]. - EUDA has also entered the Malaysian market with a direct selling license and is exploring opportunities in India through a partnership with SafeRock India Private Limited [7]. Product Development - The upgraded EUDA Helixé 2.0 product was launched in January 2026, focusing on long-term health and anti-aging, and has received Halal certification for global marketing [6]. - The sales forecast for the Helixé product has been revised down due to adjustments in marketing activities, with management still confident in achieving a long-term sales target of 500,000 bottles [6]. Token Integration - EUDA plans to launch a utility cryptocurrency called "QB" to create a token-based digital health and rewards platform, aiming to enhance user loyalty and integrate decentralized finance with healthcare [8].

Investment Rating - The report maintains a "Buy" rating for EUDA Health Holdings Limited with a target price of $2.75, down from a previous target of $6.00 [10]. Core Insights - EUDA has made significant progress in expanding its stem cell business, transitioning from a third-party distributor to a vertically integrated stem cell therapy company capable of rapid growth in China [10]. - Despite delays in the Helixé product's progress leading to a reduction in short-term revenue forecasts, the management's focus on building a portfolio of longevity and health products remains attractive for long-term growth [10]. - The revenue forecast for 2026 has been adjusted down to $27.23 million, reflecting a decrease in expected sales of the Helixé product from 105,000 bottles to 50,000 bottles [9][10]. Market Data - Current stock price is $0.73 with a market capitalization of $36.73 million [1]. - The company has a 52-week trading range of $0.70 to $4.30 and an average daily trading volume of 523,000 shares [1]. - Institutional ownership is at 2%, while insider ownership stands at 37% [1]. Financial Overview - The company reported cash of $0.17 million, short-term debt of $2.06 million, and a long-term debt of $0.00 million [1]. - The EBITDA for the past 12 months is $(1.85) million, and the operating cash flow is $(1.99) million [1]. - Revenue projections for 2023, 2024, and 2025 are $3.71 million, $4.01 million, and $9.23 million respectively [1]. Business Expansion - In January 2026, EUDA agreed to a convertible loan of 6 million RMB to upgrade its cGMP production facilities in Shenzhen, aimed at creating an advanced center for stem cell therapy [2]. - The company has launched a nationwide stem cell extraction, cryopreservation, and clinical delivery platform in collaboration with Inno and Wuhan Kane Hospital [3]. - EUDA has also obtained a direct selling license in Malaysia and entered the Indian market through a partnership with SafeRock India Private Limited [7]. Product Development - The upgraded EUDA Helixé 2.0 product was launched in January 2026, featuring a smaller capsule size and enhanced formulation targeting long-term health and anti-aging [6]. - The product has received Halal certification, allowing it to be marketed to the global Muslim market [6]. Token Integration - In December 2025, EUDA announced plans to create a token-based digital health and rewards platform using a utility cryptocurrency named "QB" [8]. - The QB token is expected to facilitate payments, rewards, and access to EUDA's products and services, enhancing user loyalty to its ecosystem [8].